Pulsed Low Dose Rate Radiation With Concurrent Chemotherapy for Non-Small Cell Lung Cancer and Esophageal Cancer

Inclusion Criteria

• •1. Patient must have pathologically-confirmed and previously untreated:
• •* Non-small cell lung cancer, Stage IIIA (T1-3 N2 M0); OR
• •* Localized esophageal cancer, ≥T2, or N+, and M0 according to the American Joint Committee on Cancer (AJCC) 7th edition staging.
• •2. The planned treatment regimen must be concurrent chemoradiation with Carboplatin-Paclitaxel followed by surgery.
• •3. Age \> 18 years.
• •4. Eastern Cooperative Oncology Group (ECOG) performance status is 0-1.
• •5. Laboratory studies must meet each of the following criteria (with labs drawn within 4 weeks prior to the registration):
• •* Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3
• •* Platelets ≥100,000 cells/mm3
• •* Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable)
• •* Creatinine ≤2 X the upper limit of normal
• •* Bilirubin ≤ 1.5 X upper limit of normal
• •* Aspartate transaminase (AST) ≤ 3 X upper limit of normal
• •6. Men and women of childbearing potential must be willing to exercise an effective form of birth control (abstinence/contraception) while on study and for 3 months after therapy completed.
• •7. Patients must be able to read and write English to comply with the questionnaire portions of the protocol.
• •8. Subjects must sign a written informed study consent and HIPAA consent prior to performance of study-specific procedures or assessments and must be willing to comply with treatment and follow up.